1 January 2021 in Translational and Clinical Pharmacology
Li Y, et al. Transl Clin Pharmacol. 2021 Dec;29(4):216-225. https://doi.org/10.12793/tcp.2021.29.e19
2 June 2025 in Kidney Research and Clinical Practice
Background: The heterogeneity of chronic kidney disease (CKD) and fragmented analysis methods hinder the precise identification of novel biomarkers. We addressed this challenge using two independent cohorts to integrate genomics and metabolomics, aiming to identify cause-specific biomarkers for CKD in the Korean population. Methods: A longitudinal genome-wide association study using the Cox proportional hazards model was conducted using the Ansan and Ansung cohort. To validate these genomic biomarkers and integrate them with plasma metabolomics biomarkers, we utilized a hospital-based biopsy cohort to identify cause-specific CKD biomarkers. Within the biopsy cohort, we analyzed four disease subsets, including type 2 diabetic kidney disease (DKD), hypertensive nephropathy (HN), immunoglobulin A nephropathy (IgAN), and membranous nephropathy (MN), and compared them with healthy individuals. Significant single nucleotide polymorphisms(SNPs) and metabolites for each CKD subset were identified through logistic regression and correlation-based network analyses. Subsequently, we analyzed the risk of disease progression associated with the identified pairs. Results: A total of 448 variants associated with CKD occurrence were identified, with significant differences in several genetic variants and metabolites observed among patients with DKD, HN, IgAN, and MN compared to healthy individuals. Among 36 SNP-metabolite pairs, those involing FOXB1 and ZFP42 were associated with DKD, whereas pairs involving MMRN1 and SYNJ2 were linked to MN. Notably, the rs1025170 variant in FOXB1 and tyrosine pair was correlated with DKD progression. Conclusion: Integrating genomics and metabolomics across independent cohorts enables the discovery of cause-specific biomarkers for the occurrence and progression of CKD in the Korean population.
4 December 2021 in Clinical and Translational Science
Five‐fluorouracil (5‐FU) is a chemotherapeutic agent that is mainly metabolized by the rate‐limiting enzyme dihydropyrimidine dehydrogenase (DPD). The DPD enzyme activity deficiency involves a wide range of severities. Previous studies have demonstrated the effect of a DPYD single nucleotide polymorphism on 5‐FU efficacy and highlighted the importance of studying such genes for cancer treatment. Common polymorphisms of DPYD in European ancestry populations are less frequently present in Koreans. DPD is also responsible for the conversion of endogenous uracil (U) into dihydrouracil (DHU). We quantified U and DHU in plasma samples of healthy male Korean subjects, and samples were classified into two groups based on DHU/U ratio. The calculated DHU/U ratios ranged from 0.52 to 7.12, and the two groups were classified into the 10th percentile and 90th percentile for untargeted metabolomics analysis using liquid chromatography‐quantitative time‐of‐flight‐mass spectrometry. A total of 4440 compounds were detected and filtered out based on a coefficient of variation below 30%. Our results revealed that six metabolites differed significantly between the high activity group and low activity group (false discovery rate q‐value < 0.05). Uridine was significantly higher in the low DPD activity group and is a precursor of U involved in pyrimidine metabolism; therefore, we speculated that DPD deficiency can influence uridine levels in plasma. Furthermore, the cutoff values for detecting DPD deficient patients from previous studies were unsuitable for Koreans. Our metabolomics approach is the first study that reported the DHU/U ratio distribution in healthy Korean subjects and identified a new biomarker of DPD deficiency.
19 August 2025 in Metabolomics
Introduction: WK0202, a β-lapachone derivative under clinical development, activates NAD(P)H quinone dehydrogenase 1 (NQO1), acting as a detoxifying and antioxidant agent. In this study, a metabolomics investigation of β-lapachone derivatives in humans is performed to characterize drug-induced alterations in endogenous metabolic pathways. Objectives: This study investigated metabolic alterations induced by WK0202 administration and their potential association with its therapeutic mechanism and efficacy. Using targeted and untargeted metabolomics approaches, we identified potential pharmacodynamic biomarker candidates that may reflect the drug’s activity and metabolic effects. Methods: Plasma samples from healthy subjects who received multiple doses of WK0202 were compared with a placebo control group. The metabolomic profiles were compared pre- and post-dose to identify significant metabolic changes. Significant metabolites were identified using statistical analyses, focusing on key metabolic pathways. To further investigate NQO1 genotype effects, Spearman correlation analysis was performed between post/pre-dose concentration ratios and genotypes. Results: Following WK0202 administration, significant changes were observed in the alanine, aspartate and glutamate metabolism, arginine biosynthesis, and lipid metabolism. Although most metabolites were not strongly dependent on NQO1 genotype or dose group, they exhibited an overall consistent trend. These alterations were indicative of Nrf2 pathway activation, possibly by NQO1-mediated drug activity. Conclusion: These metabolic alterations highlight the potential of endogenous metabolites as surrogate markers for identifying novel therapeutic targets and assessing the efficacy of WK0202 in future clinical studies.
1 January 2025 in Translational and Clinical Pharmacology
Kim H, et al. Transl Clin Pharmacol. 2025 Jun;33(2):66-79. https://doi.org/10.12793/tcp.2025.33.e7